| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CDF; HGF; HSF; BSF2; IL-6; BSF-2; IFNB2; IFN-beta-2 |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于IL6抗体的简要参考文献(基于公开研究，部分信息可能需进一步验证)：
---
1. **文献名称**: *Interleukin-6 receptor inhibition with tocilizumab in patients with COVID-19: a randomised controlled trial*
**作者**: The RECOVERY Collaborative Group
**摘要**: 该研究评估了IL-6受体抗体托珠单抗(tocilizumab)治疗COVID-19重症患者的疗效，发现其可降低需机械通气患者的死亡率，并改善临床结局。
---
2. **文献名称**: *IL-6 in inflammation, immunity, and disease*
**作者**: Kishimoto T.
**摘要**: 综述性文章，系统阐述了IL-6在炎症和免疫中的核心作用，并讨论了靶向IL-6信号通路(如托珠单抗)在治疗类风湿性关节炎等自身免疫疾病中的应用机制。
---
3. **文献名称**: *Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease*
**作者**: van Rhee F. et al.
**摘要**: 研究报道了IL-6抗体司妥昔单抗(siltuximab)在治疗多中心型Castleman病(一种淋巴增生性疾病)中的显著疗效，证实其可缓解症状并抑制疾病进展。
---
4. **文献名称**: *Targeting interleukin-6 in inflammatory autoimmune diseases and cancers*
**作者**: Tanaka T. & Narazaki M.
**摘要**: 探讨了IL-6在自身免疫疾病和癌症中的病理作用，总结了针对IL-6或其受体的抗体药物(如托珠单抗)的临床前及临床研究进展。
---
如需具体文献全文或细节，建议通过PubMed或Web of Science检索DOI或PMID进一步获取。
Interleukin-6 (IL-6) is a multifunctional cytokine involved in immune regulation, inflammation, hematopoiesis, and metabolic processes. Dysregulated IL-6 signaling is implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis), autoimmune disorders, and severe conditions like cytokine release syndrome (CRS). IL-6 exerts effects by binding to membrane-bound or soluble IL-6 receptors (IL-6R/α), forming complexes with glycoprotein 130 (gp130/β) to activate downstream JAK/STAT pathways. Targeting IL-6 or its receptors has emerged as a therapeutic strategy.
IL-6 antibodies are biologic agents designed to neutralize IL-6 or block its receptor interactions. Tocilizumab, a humanized anti-IL-6R monoclonal antibody, was the first FDA-approved IL-6 inhibitor (2005), widely used for autoimmune diseases and COVID-19-associated CRS. Siltuximab, targeting IL-6 directly, is approved for multicentric Castleman disease. These antibodies suppress pro-inflammatory signaling, reducing tissue damage and disease progression. However, they may increase infection risks due to immunosuppression.
Recent advances include novel anti-IL-6 antibodies with enhanced specificity or half-life, and bispecific antibodies combining IL-6 inhibition with other targets. Research also explores their roles in cancer and neurodegenerative diseases. Despite challenges in balancing efficacy and safety, IL-6 antibodies remain pivotal in precision immunomodulation, reflecting the cytokine's central role in pathophysiology.
×
